Posts

Parabilis’ record $670M IPO to fund cancer drug and platform expansion

on

Parabilis preps $413M IPO to fuel desmoid tumor drug into phase 3

on

Regeneron doubles down on CytomX despite other pharma exits, expanding pact to up to ~$4 billion potential value

on

Parabilis reveals IPO plans the day after Regeneron deal as listings heat up

on

Regeneron Signs $2.3 Billion Pact with Parabilis for Novel ADC-Like Antibody–Helicon Conjugates

on

Regeneron's Eylea Quarterly Sales Drop Below $1B for First Time in 8 Years Amid Competition and Shift to High-Dose Version

on

Regeneron Among Remaining Holdouts in Trump's Most-Favored-Nation Drug Pricing Deals

on

Regeneron Enters Radiopharma with $2.1B Biobucks Deal with Australia's Telix

on

FDA Action Alert: Upcoming Decisions on Sanofi/Regeneron, Merck, REGENXBIO and More in February 2026

on

JPM26 Day 3: Sanofi CEO on RSV Scrutiny and Regeneron Dupixent Defense

on

Tessera Therapeutics Strikes $150M Partnership with Regeneron for Gene Writing Therapy

on

Tessera Therapeutics Advances Gene Writing Technology with Major Funding and Strategic Partnerships

on

Dupixent Gains EU Approval as First Targeted Therapy for Chronic Spontaneous Urticaria in Over a Decade

on

FDA Grants Regeneron Two Eylea HD Approvals in One Day

on

Zag Bio Launches with $80M to Teach the Immune System to Make Better Tregs

on

Regeneron and ModeX Forge Potential $1 Billion+ Collaboration to Develop Multispecific Antibody Drugs

on

Regeneron and ModeX Forge Potential $1 Billion+ Collaboration to Develop Multispecific Antibody Drugs

on

Regeneron Heads to FDA Seeking Approval for Game-Changing Hearing Loss Gene Therapy

on

Regeneron Prepares U.S. Submission for Garetosmab After Breakthrough Phase III Result in Ultra-Rare FOP

on

Regeneron and Sandoz Settle Eylea Biosimilar Patent Dispute

on